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Emerging roles of JAK–STAT signaling pathways in adipocytes
Allison J. Richard and Jacqueline M. Stephens*
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803
Abstract
Twenty years ago, adipocytes were largely considered inert energy storage depots. Today, we
know that fat cells are highly insulin sensitive with significant endocrine functions. Alterations in
adipocyte development or function can contribute to metabolic disease, in particular Type 2
diabetes. The current obesity epidemic that plagues many nations provides a strong rationale for
understanding basic adipocyte biology. The JAK–STAT signaling pathway mediates the action of
a variety of hormones that have profound effects on adipocyte development and function. In
addition, adipocytes secrete hormones that utilize this signaling pathway. This review summarizes
research on the expression and function of JAKs and STATs in adipocytes and highlights the roles
of JAK–STAT-activating cytokines in adipose tissue.
The JAK–STAT Pathway
The janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway was
originally identified through studies of the transcriptional activation of a number of genes in
response to a variety of cytokines, growth factors, and hormones (reviewed by [1,2]).
Hormones and cytokines induce a broad range of effects on a number of biological
processes and activate receptors that do not contain catalytic cytoplasmic domains. To date,
there are four identified members in the JAK kinase family (JAKs 1–3 and Tyk2), which
associate with cytokine and growth factor receptors. JAK mediated signaling results in the
activation of a signal transduction cascade involving STAT proteins. The STAT family of
mammalian transcription factors is comprised of seven proteins (STATs 1, 2, 3, 4, 5A, 5B,
and 6) that can be tyrosine phosphorylated in response to ligand induced receptor
stimulation. Tyrosine phosphorylation results in dimer formation and translocation to the
nucleus where STATs bind DNA and positively or negatively regulate transcription. The
specificity of STAT activation and function is not completely understood. However,
specificity is determined, at least in part, by the receptor and the specific STAT protein,
whose distribution and function are each unique [3]. Other conditions such as serine
phosphorylation, dimer composition, and the presence of other proteins associated with the
STAT dimers may also confer STAT specificity. Hence, the regulation of tissue-specific
genes and the ability to have cell specific tasks appears to be an important physiological role
of the JAK–STAT pathway. As discussed herein, the expression of several STATs is
modulated during adipogenesis and an adipogenic role for STAT5 is well established.
Additional functions of JAK–STAT signaling in adipocytes include the transcriptional
regulation of genes involved in insulin action and lipid and glucose metabolism.
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Expression and function of JAKs in adipocytes
There have been very few studies focusing on JAK expression, activation, and function in
fat cells and adipose tissue. In general, these kinases are largely controlled by tyrosine
phosphorylation, rather than by expression levels. The ubiquitously expressed JAKs 1 and 2
are present at similar levels in preadipocytes and adipocytes [4], and they are expressed in
adipose tissue in vivo [5]. There is one study that indicates Tyk2 and JAK3 are expressed in
adipose tissue [5]. However, adipose tissue is comprised of many cell types, and there is no
evidence that these two JAK family members are expressed in mature fat cells. Thus, it is
highly likely that JAK–STAT signaling in adipocytes occurs primarily via JAKs 1 and 2.
Both preadipocytes and adipocytes are responsive to hormones and growth factors which
activate JAKs 1 and 2, including growth hormone (GH), prolactin (PRL), interferon gamma
(IFNγ), leukemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1),
ciliary neurotrophic factor (CNTF) [6–15]. Currently, there is no evidence that JAKs play a
STAT independent role in modulating adipocyte differentiation. However, several cytokines
that inhibit adipogenesis, including IFNγ [16,17], OSM [18,19], and neuropoietin (NP) [20],
are potent activators of JAK kinases. To date, only JAKs 1 and 2 have been detected in
adipocytes and their roles are solely attributed to their ability to be activated by cytokines
and confer STAT activation. There is one exception, however, in which JAK2 was shown to
physically interact with aP2 in adipocytes [21]. The aP2 protein is a lipid binding protein
that is highly expressed in fat cells and is likely the most abundantly expressed protein in
mature adipocytes. It has been shown that aP2 interacts with the unphosphorylated form of
JAK2, and the results of this study suggest that ligand-bound aP2 decreases JAK2 signaling
[21]. In summary, there is a paucity of data regarding the role of JAKs in adipocytes. Thus,
additional investigations will be required to further elucidate the STAT-dependent and/or
independent functions of these kinases in fat cells.
STAT expression and function in adipocyte development
The first studies on STAT expression in adipocytes, performed in murine 3T3-L1 cells,
demonstrated that the levels of STATs 1, 3, 5A and 5B are modulated during adipogenesis,
whereas STAT6 expression is not regulated during fat cell development and is uniform in
preadipocytes and adipocytes [22,23]. To date, there is no evidence that STATs 2 and 4 are
expressed in fat cells. In cultured murine and human adipocytes, the protein levels of STATs
3 and 5 are upregulated during differentiation [22,23], implicating a role for these STATs in
adipogenesis. STAT1, on the other hand, may not play the same role during murine and
human adipocyte differentiation. STAT1 exhibits opposing differentiation-dependent
expression patterns in 3T3-L1 fat cells [22] and in cultured subcutaneous human adipocytes
[23]. Also, mice with a targeted disruption of the Stat1 gene do not exhibit di fferences in
weight gain compared to wild type mice, and with the exception of IFN-dependent
responses, biologic responses to other cytokines were not defective [24]. While the
relevance of modulation of STAT1 expression during adipocyte development has not yet
been revealed, several studies discussed herein examined the contribution of STAT3 and
STAT5 on fat cell differentiation.
Adipogenesis is governed by a highly coordinated and temporally defined series of events.
The JAK2/STAT3 pathway is activated (i.e. STAT3 is tyrosine phosphorylated and
translocated to the nucleus) early during adipogenesis (first 2 – 48 hours following induction
of preadipocyte differentiation) [25–27] and is involved in achieving maximal adipocyte
differentiation potentially through modulation of C/AAAT enhancer binding protein β (C/
EBPβ) transcription [27]. Selective inhibitors of the JAK2/STAT3 signaling pathway and
STAT3 activation, as well as STAT3 siRNA and a dominant-negative STAT3, all
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suppressed adipogenesis in vitro [26]. Additionally, activation of protein inhibitor of
activated STAT3 (PIAS3), a constitutively expressed repressor of STAT3, is associated with
inhibition of adipogenesis in 3T3-L1 cells [28]. Of note, a peroxisome proliferator-activated
receptor gamma (PPARγ) agonist, which did not alter RNAi-induced STAT3 inactivation
eliminates the suppression of preadipocyte differentiation mediated by inhibition of STAT3,
suggesting that STAT3 regulation of adipogenesis occurs upstream of PPARγ activation
[26]. Collectively, these studies indicate a role of STAT3 activation in the modulation of
adipogenesis. Additional studies have shown that activation of STAT3 may promote
adipogenesis via a critical role in mitotic clonal expansion, a proliferative phase that occurs
immediately following induction of adipogenesis and is necessary for differentiation of 3T3-
L1 fat cells [25,29,30]. Further investigations probing JAK/STAT3 signaling at various
stages of adipogenesis in vitro and in vivo are necessary to better understand the role of
STAT3 in fat cell development.
Although STAT3’s involvement in fat cell differentiation is not well defined, a role for
STAT5 in adipogenesis is strongly supported (Table 1). Numerous lines of evidence have
revealed the importance of STAT5 proteins, in addition to C/EBPs α, β, and δ, PPARγ, and
several other adipogenic factors, as transcriptional regulators of fat cell development
(reviewed by [20]). As shown in Figure 1, which depicts the expression profiles of several
important adipogenic transcription factors, the induction of STAT5 protein expression is
coordinately regulated with both PPARγ and C/EBPα. These corresponding regulation
patterns have been demonstrated under a variety of conditions in 3T3-L1 cells [4]. Ectopic
expression of C/EBPs β and δ in non-precursor cells confers adipogenesis [31], which is
accompanied by STATs 5A and 5B accumulation [32]. It should be noted that the increased
expression of STAT5 proteins is not typically observed until after the induction of C/EBPα
and PPARγ, yet the activation of STAT5 proteins during adipogenesis occurs prior to the
upregulation of PPARγ expression in 3T3-L1 cells [33] (Figure 1). In fact, both STAT5
proteins are tyrosine phosphorylated and translocate to the nucleus within 15 minutes after
preadipocytes are induced to differentiate [33,34].
Additionally, several studies investigating the action of growth hormone in promoting
adipocyte differentiation have demonstrated a vital role of STAT5 in mediating the action of
GH and conferring adipogenesis. In 3T3-F442A preadipocytes, the ability of growth
hormone to modulate adipogenesis is attenuated by STAT5 anti-sense oligonucleotides [35],
and constitutively active STAT5 is capable of replacing the requirement for growth hormone
in adipogenesis of these cells [36]. Ectopic expression studies of STATs 5A and 5B further
establish the adipogenic capacity of STAT5 proteins in vitro and in vivo. Ectopically
expressed STAT5A induces adipocyte conversion of 3T3-L1 preadipocytes [37] and two
different non147 precursor cell lines [33]. Interestingly, STAT5B was not capable of
conferring adipogenesis in non-precursor cells [33]. We have also demonstrated that ectopic
expression of STAT5A in Swiss 3T3 cells results in the formation of ectopic fat pads in vivo
in athymic mice [38].
Coupled with observations in STAT5 null mice, which have fat pads one-fifth normal size
[39], the data strongly support that activation of STAT5 proteins is an important driver of
adipogenesis both in vitro and in vivo. Moreover, this hypothesis is supported by work
demonstrating that STAT5 induces PPARγ expression in coordination with C/EBPβ/δ and
also directly stimulates PPARγ transcriptional activity [8], thus suggesting that STAT5
activation drives adipogenesis by inducing PPARγ expression and activity. Furthermore, it
has been shown in vitro that STAT5B, but not 5A, binds and transactivates a region of the
PPARγ3 promoter [40], an alternative promoter restricted to adipose tissue, macrophages,
and colon that contributes to PPARγ1 expression [41]. Of note, a mutation based on a
naturally occurring polymorphism that is associated with altered lipid homeostasis is located
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within the putative STAT binding site of this promoter and eliminates STAT5B binding and
activation of a PPARγ3 reporter construct [40].
In summary, the expression of STATs 1, 3, 5A and 5B are modulated during adipocyte
development. Whereas the adipogenic capabilities of STATs 1 and 3 are not well defined,
STAT5 proteins, particularly STAT5A, are activated and induced during adipogenesis and
play an important role in adipose tissue development (Table 1). As discussed in the next
section, to date only a few STAT target genes in adipocytes are known. Identification of the
STAT-regulated genes in fat cells and examination of how these gene targets might differ
during the adipogenic program will be required to fully understand the primary functions of
STAT family members in adipocytes.
STAT target genes in mature adipocytes
The tissue distribution of each STAT is unique, and it is widely accepted that STAT proteins
have cell-specific functions. Thus, the regulation of tissue-specific genes may be a
physiological role for these proteins. Target genes for STATs 1 and 5 in adipocytes have
been identified, and their gene products influence adipogenesis, insulin action, and fat and
carbohydrate metabolism.
As indicated, studies have revealed the importance of STAT5 proteins during adipogenesis
in vitro and in vivo [33,39]. STAT5 proteins are capable of directly binding the PPARγ3
promoter [40] and can transactivate the PPARγ2 and PPARγ3 promoters [8,40]. Although a
number of transcription factors have profound effects on adipogenesis, PPARγ is a critical
transcriptional regulator facilitating fat cell differentiation. The gene encoding PPARγ is a
STAT5 target during adipocyte development and its modulation by STAT5 likely plays a
role in the ability of STAT5 to promote adipocyte differentiation.
In adipocytes, studies also identified PPARγ as a STAT1 target gene. Based on the
consensus sequence of interferon-γ-activated site (GAS) elements, which are known to
mediate IFNγ-sensitive regulation in a STAT-dependent manner, a potential STAT1 binding
site was identified in the PPARγ2 promoter. Indeed, STAT1 homodimers bind an IFNγ
responsive site within the PPARγ2 promoter in 3T3-L1 adipocytes [42]. These data suggest
that IFNγ-induced repression of PPARγ2 [43] is mediated by the direct action of STAT1 on
the PPARγ2 promoter. Modulation of both PPARγ activation pathways and IFNγ signaling
has been associated with the development of insulin resistance [9,43,44]. Accordingly,
STAT1 likely mediates the ability of IFNγ to induce insulin resistance [9,43,45,46] and
block adipogenesis [16,17] via transcriptional regulation of PPARγ levels. In another study,
an IFNγ-sensitive binding site for STAT1 was discovered in the murine lipoprotein lipase
(LPL) promoter [47]. LPL is the rate-limiting enzyme that catalyzes the hydrolysis of serum
triglycerides from lipoproteins into free fatty acids for uptake and storage in adipose tissue
(reviewed in [48]). In 3T3-F442A adipocytes, IFNγ-activated STAT1 binds to the LPL
promoter in a manner that is consistent with IFNγ-induced repression of LPL expression and
inhibition of LPL activity [16,49] and lipolysis [50]. While STAT3 also exhibits tyrosine
phosphorylation and nuclear translocation in response to IFNγ, STAT1 is a more robust
mediator of IFNγ signaling in murine and human adipocytes [6,9,10]. As such, STAT3 was
unable to bind to the identified STAT1 binding sites within the PPARγ promoter [42], and
LIF, a potent STAT3 activator, does not confer binding of STAT3 to the IFNγ sensitive
region of the LPL promoter [47].
Additional studies have focused on the identification of STAT 5 target genes in mature fully
differentiated adipocytes. The promoter for acyl CoA oxidase (AOX), the rate limiting
enzyme in peroxisomal fatty acid β-oxidation, contains a STAT5 binding site that modulates
its gene expression in fat cells [51]. Transfection studies have shown that the promoter
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activity of aP2, an abundantly expressed lipid binding protein in fat cells, can be activated
by STAT5 [52]. Conversely, STAT5 mediates the inhibition of aP2 expression in rat
primary preadipocytes [53], which was the first study to suggest that STAT5 proteins could
act as transcriptional repressors. Since that time, our own research has revealed that
STAT5A can act as a transcriptional repressor in adipocytes. A STAT5A binding site in the
murine fatty acid synthase (FAS) promoter mediates the repression of FAS transcription that
occurs with prolactin treatment [54]. FAS catalyzes the synthesis of long chain fatty acids
and is the key enzyme in de novo lipogenesis. In addition to modulation of genes associated
with lipid metabolism, STAT5 can also modulate pyruvate dehydrogenase kinase (PDK)-4,
a known regulator of glycolysis, that is highly induced in adipocytes by GH or PRL in a
STAT5-dependent manner [55]. Under these conditions, the induction of PDK4 is
accompanied by insulin resistance. It is well known that PRL and GH are important
modulators of lipid metabolism and are also potent inducers of STAT5 in adipocytes [6,52].
Hence, many of the metabolic actions of these hormones could be mediated by STAT5’s
direct modulation of target genes. Unfortunately, relatively few STAT5 target genes have
been identified in adipocytes. Nonetheless, we hypothesize that several other STAT5A
target genes that play a role in lipid or glucose metabolism will be identified.
STAT3 is abundantly expressed in adipocytes [22,23], mediates the action of numerous
cytokines in fat cells (Table 2), and as reviewed in the previous section may play a role in
adipogenesis. However, with the exception of C/EBPβ as a potential STAT3 gene target
activated early in the adipogenic program [27], to date no adipocyte-specific direct target
genes have been identified for STAT3. Although STAT6 is equivalently expressed in
preadipocytes and throughout fat cell differentiation [22], only IL-4 has been shown to
activate this transcription factor in 3T3-L1 preadipocytes but not in adipocytes [56]. Thus,
activators, functions, and gene targets of STAT6 in both preadipocytes and adipocytes
remain to be elucidated. Overall, relatively few STAT-regulated genes have been identified
in adipocytes. Nonetheless, the STAT 1, 3, and 5 target genes identified thus far encode
proteins that are important for fat cell development and for adipocyte-specific functions,
such as insulin sensitivity and lipid and carbohydrate metabolism. Although STATs were
originally identified as positive regulators of transcription, they act as both transcriptional
activators [8,27,40,51,52,55] and repressors [42,47,53,54] in fat cells. Further studies in both
cultured adipocytes and in adipose tissue are needed to reveal the complete regulatory
potential of the STAT family members in adipocytes.
Distinct functions of STAT5 in preadipocytes and adipocytes
Studies on the identification of STAT5 target genes in adipocytes suggest that these
transcription factors modulate gene expression in a manner that favors a reduction in lipid
synthesis and/or storage and an increase in lipid release. STAT5A represses the expression
of fatty acid synthase [54], an important enzyme in endogenous lipid synthesis. Also,
STAT5 inhibits the expression of aP2 [53], a lipid binding protein in adipocytes. The two
hormones that have been shown to induce activation of STAT5 proteins in adipocytes are
GH and PRL (Table 2). For decades scientists have known that GH reduces adipose tissue
mass and there is also evidence of anti-lipogenic effects of PRL [57–60]. A clear role of
STAT5 proteins in the ability of GH to induce lipolysis was demonstrated in STAT5 null
mice. In these studies, GH was unable to induce lipid release in cells that lack both STAT5
proteins [61]. Collectively, these observations demonstrate anti-lipogenic roles of STAT5
proteins in adipocytes and in adipose tissue.
As already discussed, numerous studies have demonstrated pro-adipogenic effects of STAT5
and have shown that the expression and activation of STAT5 proteins promotes lipid
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accumulation in a large variety of model systems (Table 1). Therefore, the role of STAT5 is
adipogenic in preadipocytes and anti-lipogenic in mature adipocytes (Figure 2).
JAK–STAT activators in adipose tissue
As indicated, adipocytes are responsive to several JAK/STAT activating cytokines and
hormones including LIF, OSM, CT-1, interleukin (IL)-6, CNTF, NP, GH, PRL, and IFNγ
(Table 2). Most of these observations are based on in vitro studies of cultured adipocytes.
However, there is also sufficient and compelling evidence to show that adipose tissue in
vivo is responsive to these JAK–STAT activators [12,62,63]. As shown in Figure 3,
adipocytes contain receptors for these ligands, most of which are present in circulation. An
important function of adipocytes is the production of a variety of endocrine mediators. Of
note, there are four JAK–STAT activating hormones which have been shown to be produced
from adipocytes (Figure 3), one being leptin. Leptin is an important endocrine hormone that
serves as an adiposity signal and can affect food intake and energy expenditure. Of note, the
majority of leptin is produced and secreted from adipocytes and the primary target tissue is
the arcuate nucleus. Leptin binding to its receptor within this feeding center in the
hypothalamus results in JAK2, STAT3, and STAT5 activation. In leptin receptor-deficient
mice, analysis of mutant leptin receptor knock-ins has revealed distinct roles of STAT3 and
STAT5 in leptin action [64–67]. Besides leptin, other JAK–STAT activating hormones have
also been shown to be produced from adipocytes including IL-6 [68,69], CT-1 [70], and
PRL [71–74].
Adipose tissue is largely comprised of adipocytes, but like other tissues contains endothelial
cells, connective tissue, and other types of stromal cells. The presence of infiltrating immune
cells, such as macrophages and T cells is well documented and studies in the last decade
suggest that these cells are modulated in conditions of obesity and Type 2 diabetes. IFNγ is
produced from both natural killer (NK) cells [75] and T cells [76–79] present in adipose
tissue. IFNγ can inhibit the differentiation of preadipocytes [16,17], induce insulin resistance
in mature adipocytes [9,43], and decrease PPARγ expression by targeting this nuclear
receptor to the ubiquitin proteasome system for degradation in adipocytes [80]. It is highly
likely that the production of IFNγ from infiltrated immune cells acts in a paracrine fashion
on adjacent adipocytes to result in insulin resistance. Clearly, JAK–STAT signaling
pathways play an important role in the majority of cell types that are found in adipose tissue.
Although endothelial cells have endocrine functions, there is no evidence of JAK–STAT
producing hormones from these cells. However, it is probable that the production of JAK–
STAT ligands from adipocytes and infiltrating immune cells likely impacts the functions of
endothelial cells that reside in adipose tissue.
Concluding Remarks
A summary of the current literature on the JAK–STAT signaling pathway in fat cells and
adipose tissue reveals several conclusions. First, adipocytes and adipose tissue are highly
responsive to a wide variety of hormones and growth factors that utilize the JAK–STAT
pathway. Second, adipocytes produce hormones, such as leptin, that can act in an endocrine
manner and utilize the JAK–STAT signaling pathway in its target tissues. In addition to
leptin, other JAK–STAT ligands including CT-1, PRL, and IL-6 are produced from
adipocytes and likely act in autocrine, paracrine, and/or endocrine manners. In general, the
cell-specific functions of JAKs and STATs in adipocytes are poorly understood. However,
STAT5 clearly plays a role in adipocyte development. Whereas in preadipocytes, STAT5
proteins act in a manner that favors lipid accumulation, in mature adipocytes these
transcription factors promote lipid loss. Studies in liver indicate that JAK2 and STAT5
proteins act to prevent hepatic lipid accumulation in mice as the absence of either JAK2 [81]
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or both STATs 5A and 5B [82,83] results in fatty livers and steatosis. Collectively, these
observations suggest that STAT5 proteins in liver and fat are acting to limit lipid
accumulation in these two metabolically active, insulin responsive tissues. Studies in mice
lacking STAT3 in liver have revealed a role of this STAT in regulating glucose homeostasis
by suppressing the expression of gluconeogenic genes in the liver [84]. Ectopic expression
of STAT3 in liver shows an increase in the levels of atherogenic lipids, suggesting that
STAT3 plays a role in expression of hepatic genes involved in lipid metabolism [85].
Tissue-specific knockouts of STAT3 and STAT5 have revealed roles of these STATs in
lipid and glucose metabolism. However, to date, there is only one tissue-specific STAT
knockout in adipocytes [86].
Despite the absence of these genetically manipulated mouse models, there is sufficient data
to predict key functions of STATs in adipocytes. STAT1 is highly activated by IFNγ, whose
production is increased from infiltrating immune cells present in adipose tissue. Known
effects of IFNγ include an inhibition of adipogenesis and the induction of insulin resistance.
Mice lacking STAT1 in adipocytes may be more insulin sensitive, perhaps in a manner
similar to adipocytes that lack tumor necrosis factor (TNF) receptors [87]. However, the
inhibition in adipogenesis may also result in ectopic lipid accumulation. The loss of STAT3
in adipocytes is less clear since many cytokines and hormones activate this transcription
factor in fat cells. Although there is evidence that STAT3 plays a role in adipogenesis, these
studies are based solely on in vitro observations and likely due to alterations in clonal
expansion, a phenomenon that may only occur in vitro. The primary activators of STAT3 in
adipocytes are the gp130 cytokines. Some gp130 cytokines, like NP and OSM, inhibit
adipogenesis. Some gp130 cytokines induce insulin resistance yet others act as insulin
sensitizers. Since cells lacking STAT3 would lack the ability of the cytokines to signal
through their primary signaling pathway, it is challenging to predict the phenotype of mice
lacking STAT3 in fat cells. However, there is a transgenic mouse model where STAT3
expression was knocked out with use of aP2 Cre. The primary phenotype of this mouse was
increased weight and increased adipose tissue mass, associated with adipocyte hypertrophy
[86]. These studies suggest that STAT3 contributes to body weight homeostasis. However,
since aP2 can also be expressed in other cells, it is unclear if these observations are solely
mediated by the lack of STAT3 in adipocytes. The loss of both STAT5 proteins in
adipocytes would likely result in mice that have reduced fat pad size. We hypothesize that
these mice might have ectopic lipid accumulation, particularly if placed on a high fat diet,
which would result in insulin resistance. The loss of either STAT5A or STAT5B may result
in a similar, but less drastic phenotype than the double null mice. Although the generation of
fat-specific STAT knockout mice will shed the light on the function of these transcription
factors in fat cells, we predict that a variety of in vitro and in vivo approaches will be
required to elucidate additional functions of the JAK–STAT pathway in adipocytes.
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Figure 1. STAT5 activation and expression during adipogenesis
STAT5 represents both STAT 5A and STAT 5B. Both of these STAT5 proteins are
activated by tyrosine phosphorylation immediately after the initiation of adipocyte
differentiation in 3T3-L1 cells. The activation of STAT5 proteins precedes the induction of
C/EBPβ and C/EBPδ, two transcription factors that are induced early during adipogenesis.
Increased expression of STAT 5 proteins correlates with induction of both PPARγ and C/
EBPα. PPARγ and C/EBPα are important transcription factors in adipocyte development.
MDI refers to the hormonal cocktail used for the induction of fat cell differentiation. This
cocktail contains methylisobutylxanthine, dexamethasone, and insulin in FBS (fetal bovine
serum).
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Figure 2. Opposing functions of STAT5 in preadipocytes and adipocytes
STAT5 proteins promote adipogenesis and lipid accumulation. Inhibition of STAT5
activation or expression inhibits adipogenesis in vitro and adipose tissue development in
vivo. However, in mature adipocytes, there is strong evidence to suggest that STAT5 has
anti-lipogenic function.
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Figure 3. The JAK/STAT microenvironment in adipose tissue
Adipose tissue is largely comprised of adipocytes but also contains preadipocytes,
endothelial cells, and infiltrating immune cells, including NK cells, T cells, and
macrophages. Adipocytes are highly responsive to many hormones and growth factors that
utilize the JAK/STAT pathway. The receptors for these ligands are indicated in the diagram.
Infiltrating immune cells also produce cytokines which likely act in a paracrine fashion to
induce JAK/STAT signaling in adipocytes. Adipocytes also have important endocrine
properties and four JAK/STAT activating hormones have been shown to be produced from
adipocytes.
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Table 1
Evidence supporting adipogenic nature of STAT5.
Model System Evidence to support STAT5 is adipogenic Reference
MOUSE
3T3-L1
STAT5A and STAT5B expression induced during adipogenesis [22]
Ectopic expression promotes adipogenesis in preadipocytes [37]
Activation of STAT5 proteins occurs early in adipogenesis [33]
Dominant negative STAT5 attenuates PPARγ activity [8]
3T3-F442A
STAT5 antisense blocks GH dependent adipogenesis [35]
Constitutively active STAT5 promotes adipogenesis [36]
NIH 3T3 Ectopic expression of STAT5A alone, or with STAT5B, confers adipogenesis in these non-precursor cells [33]
Balb/c Ectopic expression of STAT5A alone, or with STAT5B, confers adipogenesis in these non-precursor cells [33]
Athymic Mice Ectopic STAT5A expression in Swiss 3T3 cells promotes adipogenesis in vivo [38]
Transgenic Mice Knockout of STAT5A and STAT5B results in mice with fat pads 1/5 normal size [39]
HUMAN Human Preadipocytes STAT5A and STAT5B expression induced during adipogenesis [23]
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Table 2























Data are mostly from in vitro observations of cultured cells
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